Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea Life Sciences HoldingsPLSH +17.24% Price-to-Tangible-Book is 4.72 as of Sep. 21, 2026. The stock has 10 warning signs investors should review. Among 839 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 95.83% on this metric.
The historical rank and industry rank for Panacea Life Sciences Holdings's Price-to-Tangible-Book or its related term are showing as below:
PLSH'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.39 Med: 49.71 Max: 99
Current: 0.47
During the past 13 years, Panacea Life Sciences Holdings's highest Price to Tangible Book Ratio was 99.00. The lowest was 0.39. And the median was 49.71.
PLSH's Price-to-Tangible-Book is ranked better than 95.83% of 839
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs PLSH: 0.47
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Panacea Life Sciences Holdings Price-to-Tangible-Book Related Terms
Panacea Life Sciences Holdings Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Price-to-Tangible-Book Chart
PLSH vs AKAN, SHPH, IMCC: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Panacea Life Sciences Holdings (PLSH) has a Price-to-Tangible-Book of 4.72 as of Sep. 21, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #35 out of 839 companies in the Drug Manufacturers industry, placing it in the top 4.2%.
Is Panacea Life Sciences Holdings' Price-to-Tangible-Book too high?
Panacea Life Sciences Holdings' current Price-to-Tangible-Book is 4.72. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.30. Panacea Life Sciences Holdings' value of 4.72 is 105.2% above this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #35 out of 839 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' Price-to-Tangible-Book compare to AKAN and SHPH?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #35 out of 839 companies for Price-to-Tangible-Book. This places Panacea Life Sciences Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 2.30. Panacea Life Sciences Holdings' value of 4.72 is 105.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.30, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Price-to-Tangible-Book of 4.72 is 105.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Price-to-Tangible-Book is 4.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Price-to-Tangible-Book of 4.72. The current Price-to-Tangible-Book is 4.72 and 105.2% above the Drug Manufacturers industry median of 2.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Price-to-Tangible-Book is 4.72 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
